BioStock: Aptahem's CEO comments on Q2 and looks ahead

For Aptahem, the second quarter continued to focus on the clinical development of drug candidate Apta-1 against sepsis. However, the company recently put the clinical phase Ia study on hold after making, what it called, interesting findings. BioStock talked to CEO Mikael Lindstam to get an update.

Read the full interview with Mikael Lindstam at biostock.se:

https://www.biostock.se/en/2023/09/aptahems-ceo-comments-on-q2-and-looks-ahead/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/